Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11938139 | 0.96 | HTR7 (0.48) | HTR7HTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL11938142 | 0.96 | HTR7 (0.48) | HTR7HTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL15614034 | 0.87 | — | — | |
| SCHEMBL5273733 | 0.87 | HTR7 (0.42) | HTR7HTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL11938143 | 0.87 | HTR7 (0.42) | HTR7HTR1ADRD2HTR2AALDH1A1 | |
| SCHEMBL5605130 | 0.85 | — | — | |
| SCHEMBL9557517 | 0.85 | — | — | |
| SCHEMBL6719978 | 0.85 | — | — | |
| SCHEMBL19021680 | 0.85 | — | — | |
| SCHEMBL12039646 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306069-A1 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS | THE UNIVERSITY OF CHICAGO (US) | 2015-10-29 | — | — | US | claimed |
| WO-2014085545-A1 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS | THE UNIVERSITY OF CHICAGO (US) | 2014-06-05 | — | — | WO | claimed |
| US-3989671-A | CHELATION, COPPER COMPOUNDS, IODINE COMPOUNDS, POLYMERIZATION CATALYSTS | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JA) | 1976-11-02 | — | — | US | claimed |
| EP-4400492-A1 | ACRIDINE COMPOUND | OSAKA UNIVERSITY (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4370507-A1 | HYDROGENATED QUINOXALINES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| CN-117940408-A | Acridine compounds | 国立大学法人大阪大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-4347597-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-04 | — | — | US | disclosed |
| US-11932657-B2 | Heterocyclic compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-19 | — | — | US | disclosed |
| CN-117616013-A | Hydrogenated quinoxalines | 大塚制药株式会社 | 2024-02-27 | — | — | CN | disclosed |
| EP-1656983-A1 | Process for deacidification of a gas with an absorbing solution in fractional regeneration | Institut Français du Pétrole (FR) | 2006-05-17 | — | — | EP | disclosed |
| EP-0915078-B1 | Process for producing di-tert-butyl dicarbonate | TOKUYAMA CORP (JP) | 2001-05-02 | — | — | EP | disclosed |
| US-6020514-A | Process for producing di-tert-butyl dicarbonate | TOKUYAMA CORPORATION (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0915078-A1 | Process for producing di-tert-butyl dicarbonate | TOKUYAMA CORPORATION (JP) | 1999-05-12 | — | — | EP | disclosed |
| US-5294531-A | BicycloUm.n.oealkane-1-ylcarbonylacetamide compound | FUJI PHOTO FILM CO., LTD. (JP) | 1994-03-15 | — | — | US | disclosed |
| US-5283166-A | Yellow dye-forming coupler and silver halide color photographic light-sensitive material containing the same | FUJI PHOTO FILM CO., LTD. (JP) | 1994-02-01 | — | — | US | disclosed |
| US-4557754-A | CHEMOTHERAPEUTIC ANTIMICROBIAL PREPARATION | INSTITUT ORGANICHESKOI KHIMII (SU) | 1985-12-10 | — | — | US | disclosed |
| US-4557754-A | CHEMOTHERAPEUTIC ANTIMICROBIAL PREPARATION | INSTITUT ORGANICHESKOI KHIMII (SU) | 1985-12-10 | — | — | US | disclosed |
| US-4113488-A | PHENOLIC COMPOUND AND SYNERGISTIC SULFIDE OR SULFOXIDE | FUJI PHOTO FILM CO., LTD. (JP) | 1978-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306069-A1 | METHODS AND COMPOSITIONS INVOLVING RAD51 INHIBITORS | RAD51, MRE11, RAD50 | HTR7 2543/4885HTR1A 2716/4885DRD2 4204/4885 |
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | HPGDS, MYADM, ACR | HTR7 907/4885HTR1A 824/4885DRD2 4363/4885 |
| US-11932657-B2 | Heterocyclic compound | AHR, PDGFRA, PDGFRB | HTR7 154/4885HTR1A 126/4885DRD2 1049/4885 |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | HTR7 154/4885HTR1A 126/4885DRD2 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.